Clinical Trials on Multiple Endocrine Neoplasia Type 2A in Japan

Total 1498 results

Takeda

Completed

A Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated With Ixazomib Plus Lenalidomide and Dexamethasone

Relapsed and/or Refractory Multiple Myeloma

Japan
Takeda

Completed

NINLARO Capsules Drug Use-Results Survey (All-Case Surveillance) "Relapsed/Refractory Multiple Myeloma"

Relapsed/Refractory Multiple Myeloma

Japan
Bayer

Active, not recruiting

Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib (JPMS-DTC)

Thyroid Carcinoma

Japan
Pfizer

Active, not recruiting

MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

Japan
National Center of Neurology and Psychiatry, Japan

Completed

Phase II Clinical Trial of OCH-NCNP1

Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis, Secondary Progressive

Japan
Takeda

Completed

A Survey on NINLARO Risk Management Plan (RMP) Material Utilization Among Pharmacists in Japan

Multiple Myeloma

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of Daratumumab in Japanese Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Japan
Kyowa Kirin Co., Ltd.

Completed

Phase 3 Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism

Primary Hyperparathyroidism | Parathyroid Carcinoma

Japan
Kyowa Kirin Co., Ltd.

Completed

An Intra-individual Titration Study of KRN1493 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism

Primary Hyperparathyroidism | Parathyroid Carcinoma | Hypercalcemia

Japan
Daiichi Sankyo Co., Ltd.

Completed

A Phase 2 Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)

Type2 Diabetes Mellitus

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of JNS002 (Doxorubicin Hydrochloride Liposome Injection) in Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Japan
Bayer

Active, not recruiting

An Observational Study to Learn More About the Impact of Gadoxetate Sodium-Enhanced Magnetic Resonance Imaging (EOB-MRI) When Used to Diagnose the Spread of Cancer From the Pancreas to the Liver in Japanese People Under Real-World Conditions

Liver Metastases | Metastatic Pancreatic Cancer | Gadoxetate Sodium-enhanced Magnetic Resonance Imaging

Japan
Celgene

Completed

Revlimid® Capsules Special Drug Use-results Survey (in Patients With Newly-diagnosed Multiple Myeloma [NDMM])

Multiple Myeloma

Japan
Bristol-Myers Squibb

Completed

Elotuzumab Safety Surveillance In Japanese Patients With Relapse Or Refractory Multiple Myeloma

Multiple Myeloma

Japan
Sanwa Kagaku Kenkyusho Co., Ltd.

Completed

Dose Adjustment Trial of SK-1403 in Hemodialysis Patients With Secondary Hyperparathyroidism

Secondary Hyperparathyroidism

Japan
Kyowa Kirin Co., Ltd.

Completed

Phase 2 Study of KHK7580

Secondary Hyperparathyroidism

Japan
Kyowa Kirin Co., Ltd.

Completed

Phase 3 Study of KHK7580

Secondary Hyperparathyroidism

Japan
Kyowa Kirin Co., Ltd.

Completed

Phase 3 Study of KHK7580

Secondary Hyperparathyroidism

Japan
Kumamoto University

Completed

Maintenance Vitamin D Therapy for Secondary Hyperparathyroidism (2HPT)

Secondary Hyperparathyroidism

Japan
Kyowa Kirin Co., Ltd.

Completed

Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Peritoneal Dialysis

Secondary Hyperparathyroidism

Japan
Sanwa Kagaku Kenkyusho Co., Ltd.

Completed

Phase 3 Study of SK-1403

Secondary Hyperparathyroidism

Japan
Sanwa Kagaku Kenkyusho Co., Ltd.

Completed

SK-1403 Long-term Treatment Study; Long-term Study in Patients With Secondary Hyperparathyroidism Receiving Hemodialysis

Secondary Hyperparathyroidism

Japan
Kyowa Kirin Co., Ltd.

Completed

Phase 3 Study of KHK7580

Secondary Hyperparathyroidism

Japan
Kosei Hasegawa, MD, PhD

Recruiting

Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer

Carcinoma, Ovarian Epithelial

Japan
GlaxoSmithKline

Active, not recruiting

An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments

Multiple Myeloma

Japan
Takeda

Recruiting

A Study of Niraparib in Patients With Ovarian Cancer in Clinical Practice

Ovarian Cancer

Japan
Otsuka Pharmaceutical Co., Ltd.

Recruiting

Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma (MM)

Japan
Osaka University

Recruiting

Targeted Alpha Therapy Using Astatine (At-211) Against Differentiated Thyroid Cancer

Thyroid Cancer

Japan
Kochi University

Completed

Tight Glycemic Control by Artificial Pancreas

Pancreatic Neoplasm

Japan
Wakayama Medical University

Unknown

Combined Resection vs. Separated Resection After Mobilization of Splenic Vein During Distal Pancreatectomy (COSMOS-DP)

Pancreatic Neoplasms

Japan
Novartis Pharmaceuticals

Terminated

Study of Afuresertib Monotherapy in Japanese Relapsed Multiple Myeloma Patients

Neoplasms, Haematologic

Japan
Osaka Medical Center for Cancer and Cardiovascular...

Completed

Chemoradiotherapy With Gemcitabine/S-1 vs Gemcitabine/S-1 for Locally Advanced Pancreatic Cancer

Pancreatic Cancer

Japan
Japan Clinical Cancer Research Organization

Completed

GEM vs GEM+TS-1 for Advanced Pancreatic Cancer

Pancreatic Cancer

Japan
Eli Lilly and Company

Completed

Study of Tabalumab (LY2127399) in Japanese Participants With Relapsed or Refactory Multiple Myeloma

Multiple Myeloma

Japan
SymBio Pharmaceuticals

Terminated

Efficacy and Safety Study of SyB L-0501 for Patients With Multiple Myeloma

Multiple Myeloma

Japan
Osaka Medical Center for Cancer and Cardiovascular...

Completed

A Study of Chemoradiotherapy Using Gem Plus Nab-paclitaxel for Pancreatic Cancer

Pancreatic Cancer

Japan
Fukushima Medical University

Unknown

Preoperative Intratumor Dendritic Cells Injection Immunotherapy for Patients With Pancreatic Cancer

Pancreatic Cancer

Japan
Eisai Co., Ltd.

Completed

Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T)

Thyroid Neoplasms

Japan
Japanese Gynecologic Oncology Group

Completed

Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Cancer

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of JNJ-54767414 (Daratumumab) in Combination With Lenalidomide and Dexamethasone in Japanese Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy and Autologous Stem Cell Transplantation

Multiple Myeloma

Japan
Mie University

Completed

Changes in Adrenal Hormones During Adrenal Radiofrequency Ablation

Adrenal Tumors

Japan
Invitae Corporation
National Cancer Center Hospital East

Recruiting

Multicenter Study of Circulating Tumor DNA in Patients With Pancreatic Cancer Using a Personalized Panel (ARTEMIS-PC)

Pancreatic Cancer

Japan
Wakayama Medical University

Unknown

Phase I Study of Neoadjuvant Chemotherapy for Patients With Borderline Resectable Pancreatic Cancer.

Pancreatic Cancer

Japan
Takeda

Completed

Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus"

Type 2 Diabetes Mellitus

Japan
Takeda

Completed

Alogliptin/Pioglitazone (Liovel) Combination Tablets Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Japan
Takeda

Completed

Specified Drug-Use Survey of Alogliptin and Metformin Hydrochloride Combination Tablets "Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Renal or Hepatic Impairment or Advanced Age"

Type 2 Diabetes Mellitus

Japan
Novartis Pharmaceuticals

Completed

Drug Interaction of Vildagliptin (LAF237) With Voglibose in Japanese Patients With Type 2 Diabetes

Type 2 Diabetes

Japan
Hoffmann-La Roche

Terminated

Study on Improvement of Blood Glucose Control in Patients With Diabetes Type 2 Using SMBG

Diabetes

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Long-term Safety Study of MP-513 as Monotherapy or in Combination With Sulfonylurea in Japanese Type 2 Diabetic Patients

Type 2 Diabetes Mellitus

Japan
Sanofi

Completed

Effectiveness and Safety of Treatment of Insulin Glargine in Type 2 Diabetes Mellitus Following Glucagon-like Peptide-1 (GLP-1) Failure (GAUDI)

Type 2 Diabetes Mellitus

Japan

3

Subscribe